Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?

Bio-Techne Corp. (TECH) has launched a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer.The research-use-only assay, which includes a qPCR detection kit and an isolation kit for cell-free DNA and exosomal RNA, will also be featured at the ongoing San Antonio Breast Cancer Symposium. The latest development is expected to bolster the company’s Diagnostics and Spatial Biology segmen ...